Skip to main content

Advertisement

SpringerLink
Log in

Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO

  • Consensus Statement
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Siris E, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the national bone health alliance working group. Osteoporos Int 25(5):1439–1443

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Berger C, Goltzman D, Langsetmo L, Joseph L, Jackson S, Kreiger N, Tenenhouse A, Davison KS, Josse RG, Prior JC, Hanley DA (2010) CaMos Research Group. Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 25(9):1948–1957

    Article  PubMed  Google Scholar 

  3. Tomkinson A, Reeve J, Shaw RW, Noble BS (1997) The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82:3128–3135

    CAS  PubMed  Google Scholar 

  4. Taranta A, Brama M, Teti A, Luca V, Scandurra R, Spera G, Agnusdei D, Termine JD, Migliaccio S (2002) The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30(2):368–376

    Article  CAS  PubMed  Google Scholar 

  5. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991–1997

    Article  PubMed  PubMed Central  Google Scholar 

  6. Modder UIL, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S (2011) Regulation of circulating sclerostin levels by sex steroids in women and men. J Bone Miner Res 26:27–34

    Article  CAS  PubMed  Google Scholar 

  7. Srivastava S, Weitzmann MN, Cenci S, Ross FP, Adler S, Pacifici R (1999) Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and Jun-D. J Clin Invest 104:503–513

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shevde NK, Bendixen AC, Dienger KM, Pike JW (2000) Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 97:7829–7834

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nakamura T, Imai Y, Matsumoto T et al (2007) Estrogen prevents bone loss via estrogen receptor alpha and induction of fas ligand in osteoclasts. Cell 130:811–823

    Article  CAS  PubMed  Google Scholar 

  10. Martin-Millan M, Almeida M, Ambrogini E et al (2010) The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 24:323–334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Manolagas SC, O’Brien CA, Almeida M (2013) The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol 9(12):699–712

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Christakos S, Dhawan P, Porta A, Mady LJ, Seth T, Milhaud G (2011) Vitamin D and intestinal calcium absorption. Mol Cell Endocrinol 347(1–2):25–29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Christiansen C, Gallagher C, Reeve J, Seeman E, Chesnut C, Parfitt A (1983) Pathogenesis and treatment of postmenopausal osteoporosis. Calcif Tissue Int 35(6):708–711

    PubMed  Google Scholar 

  14. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM (2002) Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the women’s health initiative observational study. JAMA 288(8):980–987

    Article  CAS  PubMed  Google Scholar 

  15. Beral V (2003) Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362(9382):419–427

    Article  CAS  PubMed  Google Scholar 

  16. Shufelt C, Bairey Merz CN, Pettinger MB, Choi L, Chlebowski R, Crandall CJ, Liu S, Lane D, Prentice R, Manson JE (2018) Womenʼs health initiative investigators. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. Menopause May:7

    Google Scholar 

  17. Cipriani C, Pepe J, Bertoldo F, Bianchi G, Cantatore FP, Corrado A, Di Stefano M, Frediani B, Gatti D, Giustina A, Porcelli T, Isaia G, Rossini M, Nieddu L, Minisola S, Girasole G, Pedrazzoni M (2018) The epidemiology of osteoporosis in Italian postmenopausal women according to the national bone health alliance (NBHA) diagnostic criteria: a multicenter cohort study. J Endocrinol Invest 41(4):431–438

    Article  CAS  PubMed  Google Scholar 

  18. Piscitelli P, Brandi M, Cawston H, Gauthier A, Kanis JA, Compston J, Borgström F, Cooper C, McCloskey E (2014) Epidemiological burden of postmenopausal osteoporosis in Italy from 2010 to 2020: estimations from a disease model. Calcif Tissue Int 95(5):419–427

    Article  CAS  PubMed  Google Scholar 

  19. Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) EU review panel of IOF. Osteoporosis in the European union: a compendium of country-specific reports. Arch Osteoporos 8:137–142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Nuti R, Brandi ML, Checchia G, Di Munno O, Dominguez L, Falaschi P, Fiore CE, Iolascon G, Maggi S, Michieli R, Migliaccio S, Minisola S, Rossini M, Sessa G, Tarantino U, Toselli A, Isaia GC (2018) Guidelines for the management of osteoporosis & fragility fractures. Int Emerg Medic 2018:1–18. https://doi.org/10.1007/s11739-018-1874-2

    Article  Google Scholar 

  21. Torgerson DJ, Bell-Syer SEM (2001) Hormone replacement therapy and prevention of non-vertebral fractures. A meta-analysis of randomized trials. JAMA 285:2891–2897

    Article  CAS  PubMed  Google Scholar 

  22. Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288:321–333

    Article  Google Scholar 

  23. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288:321–333

    Article  CAS  PubMed  Google Scholar 

  24. de Villiers TJ, Pines A, Panay N et al (2013) International menopause society. Updated 2013 International menopause society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16:316–337

    Article  CAS  PubMed  Google Scholar 

  25. The Women’s Health Initiative Study Group (1998) Design of the women’s health initiative clinical trial and observational study. Control Clin Trials 19(1):61–109

    Article  Google Scholar 

  26. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Writing group for the women’s health initiative investigators. Writing group for the women’s health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288(3):321–333

    Article  CAS  PubMed  Google Scholar 

  27. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Women’s health initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health Initiative randomized controlled trial. JAMA 291(14):1701–1712

    Article  CAS  PubMed  Google Scholar 

  28. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Women’s health initiative investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women’s health initiative randomized trial. JAMA 290(13):1729–1738

    Article  CAS  PubMed  Google Scholar 

  29. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Women’s health initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA. 291(14):1701–1712

    Article  CAS  PubMed  Google Scholar 

  30. Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T (2006) Women’s Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health initiative randomized trial. J Bone Miner Res 21(6):817–828

    Article  CAS  PubMed  Google Scholar 

  31. Wimalawansa SJA (1998) Four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104(3):219–226

    Article  CAS  PubMed  Google Scholar 

  32. Melton LJ 3rd, Crowson CS, Malkasian GD (1996) O’Fallon WM fracture risk following bilateral oophorectomy. J Clin Epidemiol 49(10):1111–1115

    Article  PubMed  Google Scholar 

  33. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) Committee of scientific advisors of the international osteoporosis foundation]. The use of biochemical markers of bone turnover in osteoporosis. Committee of scientific advisors of the international osteoporosis foundation. Osteoporos Int 11(S6):S2–S17

    Article  PubMed  Google Scholar 

  34. Hosking DJ, Ross PD, Thompson DE, Wasnich RD, McClung M, Bjarnason NH, Ravn P, Cizza G, Daley M, Yates AJ (1998) Evidence that increased calcium intake does not prevent early postmenopausal bone loss. Clin Ther 20(5):933–944

    Article  CAS  PubMed  Google Scholar 

  35. Komulainen MH, Kröger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R, Saarikoski S (1998) HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 31(1):45–54

    Article  CAS  PubMed  Google Scholar 

  36. Lees B (2001) Stevenson JC The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Osteoporos Int 12(4):251–258

    Article  CAS  PubMed  Google Scholar 

  37. Lufkin EG, Wahner HW, O’Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117(1):1–9

    Article  CAS  PubMed  Google Scholar 

  38. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G (1999) Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 131(12):935–942

    Article  CAS  PubMed  Google Scholar 

  39. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E (2006) Results from the estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas 55(2):162–173

    Article  CAS  PubMed  Google Scholar 

  40. Vickers MR, Martin J, Meade TW (2007) WISDOM study team. The women’s international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health 7:2–9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA 310(13):1353–1368

    Article  CAS  PubMed  Google Scholar 

  42. Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, McNamee R, Elstein M, Kay C, Seif M, Buckley H (2002) ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360(9350):2001–2008

    Article  CAS  PubMed  Google Scholar 

  43. Genant K, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H, Downs R, Mortola J, Watts N, Yang HM, Banav N, Brennan JJ, Nolan JC (1997) Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch Intern Med 157:2609–2615

    Article  CAS  PubMed  Google Scholar 

  44. Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW (2004) A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 164(8):871–879

    Article  CAS  PubMed  Google Scholar 

  45. Weiss SR, Ellman H, Dolker M (1999) A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal estradiol investigator group. Obstet Gynecol 94(3):330–336

    CAS  PubMed  Google Scholar 

  46. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health initiative randomized trials. JAMA 310(13):1353–1368

    Article  CAS  PubMed  Google Scholar 

  47. Liu JH, Muse KN (2005) The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 192(4):1316–1323

    Article  CAS  PubMed  Google Scholar 

  48. Prior JC (2018) Progesterone for the prevention and treatment of osteoporosis in women. Climacteric 21(4):366–374

    Article  CAS  PubMed  Google Scholar 

  49. Tuppurainen M, Kröger H, Saarikoski S, Honkanen R, Alhava E (1994) The effect of previous oral contraceptive use on bone mineral density in perimenopausal women. Osteoporos Int 4(2):93–98

    Article  CAS  PubMed  Google Scholar 

  50. Barrett-Connor E, Wehren LE, Siris ES, Miller P, Chen YT, Abbott TA 3rd, Berger ML, Santora AC, Sherwood LM (2003) Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the national osteoporosis risk assessment (NORA) study. Menopause 10(5):412–419

    Article  PubMed  Google Scholar 

  51. Banks E, Beral V, Reeves G, Balkwill A, Barnes I (2004) Million women study collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291(18):2212–2220

    Article  CAS  PubMed  Google Scholar 

  52. Bagger YZ, Tankó LB, Alexandersen P, Hansen HB, Møllgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34(4):728–735

    Article  CAS  PubMed  Google Scholar 

  53. Hundrup YA, Høidrup S, Ekholm O, Davidsen M, Obel EB (2004) Risk of low-energy hip, wrist, and upper arm fractures among current and previous users of hormone replacement therapy: the danish nurse cohort study. Eur J Epidemiol 19(12):1089–1095

    Article  PubMed  Google Scholar 

  54. Paganini-Hill A, Atchison KA, Gornbein JA, Nattiv A, Service SK, White SC (2005) Menstrual and reproductive factors and fracture risk: the leisure world cohort study. J Womens Health (Larchmt) 14(9):808–819

    Article  Google Scholar 

  55. Middleton ET, Steel SA (2007) The effects of short-term hormone replacement therapy on long-term bone mineral density. Climacteric 10(3):257–263

    Article  CAS  PubMed  Google Scholar 

  56. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the WHI randomized trials. JAMA 310(13):1353–1368

    Article  CAS  PubMed  Google Scholar 

  57. Lindsay R, Gallagher CJ, Kleerekoper M, Pickar JH (2002) Effects of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287:2668–2676

    Article  CAS  PubMed  Google Scholar 

  58. Prestwood KM, Kenny AM, Unson C, Kulldorf M (2000) The effect of low dose micronized 17β-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, Placebo-Controlled Study. J Clin Endocrinol Metab 85:4462–4469

    CAS  PubMed  Google Scholar 

  59. Weiss SR, Hellman H, Dolker M, Transdermal Estradiol Investigator Group (1999) A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Obstet Gynecol 94(3):330–336

    CAS  PubMed  Google Scholar 

  60. Laakkonen EK, Soliymani R, Karvinen S, Kaprio J, Kujala UM, Baumann M, Sipilä S, Kovanen V, Lalowski M (2017) Estrogenic regulation of skeletal muscle proteome: a study of premenopausal women and postmenopausal MZ cotwins discordant for hormonal therapy. Aging Cell 16(6):1276–1287

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Hevener AL, Zhou Z, Moore TM, Drew BG, Ribas V (2018) The impact of ERα action on muscle metabolism and insulin sensitivity—strong enough for a man, made for a woman. Mol Metab 15:20–34

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. ACOG Committee Opinion number 698 (2017) Hormone therapy in primary ovarian insufficiency; the 2017 hormone therapy position statement of the north American menopause society. Menopause 24(7):728–753

    Article  Google Scholar 

  63. The NAMS (2017) Hormone Therapy Position Statement Advisory Panel; The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 24(7):728–753

    Article  Google Scholar 

  64. Diez-Perez A (2006) Selective estrogen receptor modulators (SERMS). Arq Bras Endocrinol Metabol 50:720–734

    Article  PubMed  Google Scholar 

  65. Brzozowski AM, Pike ACW, Dauter Z et al (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753–758

    Article  CAS  PubMed  Google Scholar 

  66. Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators. Mechanisms of action and application to clinical practice. N Engl J Med 348:618–629

    Article  CAS  PubMed  Google Scholar 

  67. Gandolini G, Migliaccio S, Bevilacqua M, Lello S, Malavolta N (2004) Prevent, treat and maintain: a new goal for osteoporosis management in clinical practice. Aging ClinExp Res 16S(3):37–41

    Google Scholar 

  68. Lello S, Brandi ML, Minisola G, Minisola S, Genazzani AR (2011) Bazedoxifene: literature data and clinical evidence. Clin Cases Miner Bone Metab 8(3):29–32

    PubMed  PubMed Central  Google Scholar 

  69. Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW (2003) Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 10(4):337–344

    Article  PubMed  Google Scholar 

  70. Miller PD, Chines AA, Christiansen C, Hans C, Hoeck HC, Kendler DL, Michael Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-years results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525–535

    Article  CAS  PubMed  Google Scholar 

  71. Miller PD, Siris ES, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Chen YT, Berger ML, Santora AC, Sherwood LM (2002) Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the national osteoporosis risk assessment. J Bone Miner Res 17(12):2222–2230

    Article  PubMed  Google Scholar 

  72. Migliaccio S, Brama M, Spera G (2007) The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging 2(1):55–64

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of raloxifene evaluation (MORE) investigators. JAMA 282(7):637–645

    Article  CAS  PubMed  Google Scholar 

  74. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R (2002) Mulitple outcomes of raloxifene evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: 4-year results from a randomized clinical trial. J Clin Endocrinol Metab 87(8):3609–3617

    Article  CAS  PubMed  Google Scholar 

  75. Miller PD, Chines AA, Christiansen C, Hans C, Hoeck HC, Kendler DL, Michael Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year Results of a Randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525–535

    Article  CAS  PubMed  Google Scholar 

  76. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923–1934

    Article  CAS  PubMed  Google Scholar 

  77. Silverman S, Chines A, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD (2012) Bazedoxifene study group. Sustained efficacy of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 23(1):351–363

    Article  CAS  PubMed  Google Scholar 

  78. Palacios S, Silverman SL, de Villiers TJ, Levine AB, Goemaere S, Brown JP, De Cicco Nardone F, Williams R, Hines TL, Mirkin S, Chines AA (2015) Bazedoxifene study group. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause 22(8):806–813

    Article  PubMed  Google Scholar 

  79. Bachman G, Crosby U, Feldman RA, Ronkin S, Constantine GD (2011) Effects of bazedoxifene in non-flushing postmenopausal women: a randomized phase 2 trial. Menopause 18(5):508–514

    Article  Google Scholar 

  80. Reed MJ, Kloosterboer H (2004) Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas 48(S1):4–6

    Article  CAS  Google Scholar 

  81. Ederveen AG, Kloosterboer HJ (2001) Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 16:1651–1657

    Article  CAS  PubMed  Google Scholar 

  82. Langer RD, Landgren BM, Rymer J, Helmond FA (2003) OPAL investigators. The OPAL study. The OPAL study: BMD data from a three-year, double-blind, randomized study comparing the effects of tibolone, CEE/MPA and placebo in postmenopausal women. Menopause 10:586–591

    Google Scholar 

  83. Gallagher JC, Baylink DJ, Freeman R, McClung M (2001) Prevention of bone loss with tibolone in postmenopausal women; results of two-randomised, double-blind, placebo-controlled, dose finding studies. J Clin Endocrinol Metab 86:4717–4726

    Article  CAS  PubMed  Google Scholar 

  84. Rymer J, Robinson J, Fogelman I (2002) Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 5:390–398

    Article  CAS  PubMed  Google Scholar 

  85. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C et al (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359:697–708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Lello S, Capozzi A, Scambia G (2017) The tissue-selective estrogen complex (bazedoxifene/conjugated estrogens) for the treatment of menopause. Int J Endocrinol 2017:5064725

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Pazhekattu R, Lau AN, Adachi JD (2015) The tissue-selective estrogen complex: a review of current evidence. Rheumatol Ther 2(1):47–58

    Article  PubMed  PubMed Central  Google Scholar 

  88. Reginster J-Y, Ferrari S, Hadji P (2014) Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene. Curr Med Res Opin 30(6):1165–1176

    Article  CAS  PubMed  Google Scholar 

  89. Lobo R, Pinkerton JV, Gass MLS, Dorin MH, Ronkin S, Pickar JH, Constantine G (2009) Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 92(3):1025–1038

    Article  CAS  PubMed  Google Scholar 

  90. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G (2009) Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92(3):1045–1052

    Article  CAS  PubMed  Google Scholar 

  91. Mirkin S, Komm BS, Pan K, Chines AA (2013) Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 16(3):338–346

    Article  CAS  PubMed  Google Scholar 

  92. Pinkerton JV, Harvey J, Lindsay R, Pan K, Chines AA, Mirkin S, Archer DF (2014) SMART-5 investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 99:189–198

    Article  CAS  Google Scholar 

  93. Jacobsen DE, Samson MM, Kezic S, Verhaar HJ (2007) Postmenopausal HRT and tibolone in relation to muscle strength and body composition. Maturitas 58(1):7–18

    Article  CAS  PubMed  Google Scholar 

  94. Clayton AH, Goldstein I, Kim NN, Althof SE, Faubion SS, Faught BM, Parish SJ, Simon JA, Vignozzi L, Christiansen K, Davis SR, Freedman MA, Kingsberg SA, Kirana PS, Larkin L, McCabe M, Sadovsky R (2018) The international society for the study of women’s sexual health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc 93(4):467–468

    Article  PubMed  Google Scholar 

  95. Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, Kaunitz AM, Krychman ML, Parish SJ, Partridge AH, Pinkerton JV, Rowen TS, Shapiro M, Simon JA, Goldfarb SB, Kingsberg SA (2018) Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the north American menopause society and the international society for the study of women’s sexual health. Menopause 25(6):596–608

    Article  PubMed  Google Scholar 

  96. Cairoli E, Palmieri S, Goggi G, Roggero L, Arosio M, Chiodini I, Eller-Vainicher C (2018) Denosumab or oral bisphosphonates in primary osteoporosis: a “real-life” study. J Endocrinol Invest 41(8):1005–1013

    Article  CAS  PubMed  Google Scholar 

  97. Migliaccio S, Francomano D, Romagnoli E, Marocco C, Fornari R, Resmini G, Buffa A, Di Pietro G, Corvaglia S, Gimigliano F, Moretti A, de Sire A, Malavolta N, Lenzi A, Greco EA, Iolascon G (2017) Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. J Endocrinol Invest 40(12):1321–1326

    Article  CAS  PubMed  Google Scholar 

  98. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N (2017) National osteoporosis guideline group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12(1):43

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA 291:1701–1712

    Article  Google Scholar 

Download references

Acknowledgments

LV is a member of the Italian Society of Endocrinology (SIE); SL is a member of the Italian Society of Gynecology and Obstetrics (SIGO) and the Italian Society of Osteoporosis and Mineral Metabolism and Bone Diseases (SIOMMMS); SM is member of SIE and SIOMMMS; NM is a member of SIOMMMS; PV is a member of SIGO; GM is a member of SIGO.

Author information

Author notes

  1. S. Migliaccio and S. Lello Equal contribution.

Authors and Affiliations

  1. Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

    L. Vignozzi

  2. St Orsola-Malpighi Hospital, Cardio-Thoracic -Vascular Department, Program of Rheumatic and Connective Tissue Disordes and Bone Metabolic Diseases, Bologna, University of Bologna, Bologna, Italy

    N. Malavolta

  3. Department of Obstetrics and Gynecology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy

    P. Villa

  4. Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy

    G. Mangili

  5. Department of Movement, Human and Health Sciences, Unit of Endocrinology, University of “Foro Italico” of Rome, Largo Lauro De Bosis 6, 00195, Rome, Italy

    S. Migliaccio

  6. Department of Woman and Child Health, Policlinico Gemelli Foundation, Rome, Italy

    S. Lello

Authors
  1. L. Vignozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Malavolta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Villa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Mangili
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Migliaccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Lello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Migliaccio.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

No informed consent.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vignozzi, L., Malavolta, N., Villa, P. et al. Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO. J Endocrinol Invest 42, 609–618 (2019). https://doi.org/10.1007/s40618-018-0978-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-018-0978-x

Keywords

Search

Navigation